Academic Journal
Droplet Digital PCR-Based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts Helicobacter pylori Eradication Success: A New Zealand Cohort Study.
| Title: | Droplet Digital PCR-Based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts Helicobacter pylori Eradication Success: A New Zealand Cohort Study. |
|---|---|
| Authors: | Inns SJ; University of Otago, Wellington, New Zealand.; Capital Coast and Hutt Valley, Health New Zealand Te Whatu Ora, Wellington, New Zealand., Sowerbutts S; University of Otago, Wellington, New Zealand., Yumnam B; Malaghan Institute of Medical Research, Wellington, New Zealand., Payne K; Malaghan Institute of Medical Research, Wellington, New Zealand., Wheller G; Malaghan Institute of Medical Research, Wellington, New Zealand., Camberis M; Malaghan Institute of Medical Research, Wellington, New Zealand., Mules T; University of Otago, Wellington, New Zealand.; Capital Coast and Hutt Valley, Health New Zealand Te Whatu Ora, Wellington, New Zealand.; Malaghan Institute of Medical Research, Wellington, New Zealand. |
| Source: | Helicobacter [Helicobacter] 2025 Sep-Oct; Vol. 30 (5), pp. e70075. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9605411 Publication Model: Print Cited Medium: Internet ISSN: 1523-5378 (Electronic) Linking ISSN: 10834389 NLM ISO Abbreviation: Helicobacter Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford : Wiley-Blackwell Original Publication: Malden, MA : Wiley-Blackwell, c1996- |
| MeSH Terms: | Clarithromycin*/pharmacology , Clarithromycin*/therapeutic use , Helicobacter Infections*/drug therapy , Helicobacter Infections*/microbiology , Helicobacter Infections*/diagnosis , Helicobacter pylori*/drug effects , Helicobacter pylori*/genetics , Helicobacter pylori*/enzymology , Helicobacter pylori*/isolation & purification , Anti-Bacterial Agents*/pharmacology , Anti-Bacterial Agents*/therapeutic use , Polymerase Chain Reaction*/methods , Urease*/analysis , Drug Resistance, Bacterial*, Humans ; New Zealand ; Female ; Male ; Middle Aged ; Aged ; Adult ; Cohort Studies ; Treatment Outcome |
| Abstract: | Background: Helicobacter pylori (H. pylori) infection is a major cause of peptic ulcer disease and gastric cancer. Rising clarithromycin resistance has significantly reduced the efficacy of standard triple therapy. In Aotearoa New Zealand, the prevalence and impact of antibiotic resistance remain incompletely defined, limiting the development of effective treatment strategies. Methods and Aims: This study evaluated the feasibility and clinical utility of detecting clarithromycin resistance genes using droplet digital polymerase chain reaction (ddPCR) on stored Rapid Urease Test (RUT) samples-a relatively novel application of molecular diagnostics. We also assessed the association between resistance status and treatment outcomes following empiric first-line triple therapy. Patients with positive RUT tests during gastroscopy were treated with omeprazole-based triple therapy and followed up with H. pylori stool antigen testing to confirm eradication. Results: Among 84 patients, clarithromycin resistance genes were detected in 13 (15.5%). Overall eradication was achieved in 74 (88.1%) patients. However, eradication success was significantly lower in those with resistance (38.5%) compared to those without (97.2%, p < 0.001). Infection burden, treatment regimen, and duration were not associated with eradication rates, supporting resistance status as the primary determinant of treatment outcome. Resistance rates were similar between Māori and Pacific patients (18.2%) and other ethnic groups (14.8%), although sample sizes limited definitive conclusions. Conclusions: ddPCR testing on stored RUT samples is a feasible and effective method for detecting clarithromycin resistance. This study demonstrates that clarithromycin resistance, rather than infection burden, treatment regimen, or duration, drives eradication failure in New Zealand. Tailored therapy based on molecular resistance testing may enhance treatment success and support antibiotic stewardship. These findings justify the development of PCR-guided treatment pathways and provide a strong rationale for extending this approach to non-invasive stool-based testing suitable for use in primary care and screening programs. (© 2025 The Author(s). Helicobacter published by John Wiley & Sons Ltd.) |
| References: | Lancet Gastroenterol Hepatol. 2023 Jul;8(7):623-634. (PMID: 37178702) Antimicrob Agents Chemother. 2005 Apr;49(4):1600-3. (PMID: 15793150) Helicobacter. 2022 Apr;27(2):e12873. (PMID: 35151236) Gastroenterology. 2024 Feb;166(2):267-283. (PMID: 37806461) Clin Transl Gastroenterol. 2025 Feb 01;16(2):e00792. (PMID: 39620581) Dig Dis Sci. 2000 Jan;45(1):68-76. (PMID: 10695616) World J Clin Cases. 2021 Jan 6;9(1):133-147. (PMID: 33511178) Therap Adv Gastroenterol. 2023 Aug 31;16:17562848231196357. (PMID: 37667805) Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):613-629. (PMID: 34002081) IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241. (PMID: 7715068) Gut. 2012 May;61(5):646-64. (PMID: 22491499) Indian J Med Microbiol. 2017 Jul-Sep;35(3):406-409. (PMID: 29063887) Rev Argent Microbiol. 2018 Oct - Dec;50(4):359-364. (PMID: 29602600) Gut. 2021 Jan;70(1):40-54. (PMID: 32958544) Helicobacter. 2025 Sep-Oct;30(5):e70075. (PMID: 41013956) Gastroenterology. 2018 Nov;155(5):1372-1382.e17. (PMID: 29990487) Gut. 2010 Aug;59(8):1143-53. (PMID: 20525969) Dig Liver Dis. 2016 Aug;48(8):899-903. (PMID: 27211882) World J Gastroenterol. 2014 Jun 7;20(21):6547-53. (PMID: 24914376) J Clin Microbiol. 2018 Aug 27;56(9):. (PMID: 29925646) PLoS One. 2022 Apr 20;17(4):e0265322. (PMID: 35442962) Helicobacter. 2021 Aug;26(4):e12804. (PMID: 33860967) Cancer Res. 1992 Dec 15;52(24):6735-40. (PMID: 1458460) J Dig Dis. 2012 Jan;13(1):54-9. (PMID: 22188917) Gastroenterology. 2017 Aug;153(2):420-429. (PMID: 28456631) N Z Med J. 2013 Oct 18;126(1384):64-76. (PMID: 24162631) Gastroenterology. 2022 Jun;162(7):2095-2097.e2. (PMID: 35196541) |
| Grant Information: | 24/848 Health Research Council of New Zealand; New Zealand Society of Gastroenterology |
| Contributed Indexing: | Keywords: Helicobacter pylori; clarithromycin resistance; tailored therapy |
| Substance Nomenclature: | H1250JIK0A (Clarithromycin) 0 (Anti-Bacterial Agents) EC 3.5.1.5 (Urease) |
| Entry Date(s): | Date Created: 20250927 Date Completed: 20250927 Latest Revision: 20250930 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12475888 |
| DOI: | 10.1111/hel.70075 |
| PMID: | 41013956 |
| Database: | MEDLINE |
| ISSN: | 1523-5378 |
|---|---|
| DOI: | 10.1111/hel.70075 |